Several targets, such as immune checkpoints, T-cell-costimulatory factors, macrophage-coinhibitory factors, and immune-suppressive factors in the TME, are ideal for promoting immune responses
Several targets, such as immune checkpoints, T-cell-costimulatory factors, macrophage-coinhibitory factors, and immune-suppressive factors in the TME, are ideal for promoting immune responses. in the treatment of cancers, infections, and autoimmune diseases. The concept of bsAbs was first proposed by Nisonoff and Rivers[1] in 1961, and Milstein and Cuello[2] synthesized the first bsAb in 1983 via hybridoma technology. In the early period of this field, the production of bsAbs encountered several problems, such as Rabbit Polyclonal to CCR5 (phospho-Ser349) immunogenicity, low production Olmesartan medoxomil efficiency, and limited clinical application, hampering the development of this field.[3] Nonetheless, with the advances in biotechnology, several novel bsAb-synthesis platforms, such as Knob-Into-Hole, DuoBody, Crossmab, and TandAb, have emerged.[4C6] To date, hundreds of bsAbs have undergone evaluation in clinical trials worldwide. The dual specificity Olmesartan medoxomil…